CorMedix Inc. (NASDAQ: CRMD) saw its stock soar 7.42% in pre-market trading on Tuesday following the release of its stellar first-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, driving investor enthusiasm.

CorMedix reported earnings per share (EPS) of $0.30 for Q1 2025, handily beating the consensus estimate of $0.24 by 25%. This marks a remarkable turnaround from the $0.25 loss per share reported in the same quarter last year. The company's revenue also impressed, coming in at $39.08 million, surpassing analyst projections of $36 million by 8.55%. Net income for the quarter stood at a robust $20.6 million, significantly exceeding the estimated $16.4 million.

Investors were further encouraged by CorMedix's strong financial position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Looking ahead, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half 2025 sales guidance range of $62 million to $70 million. This combination of strong current performance and positive future prospects likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.